Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HOWARD J RUBENSTEIN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1376598086
CMS profile
244149
Location
SARALAND, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,704.05

108 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,686.25 105
Education $17.80 3

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 3; records 1–50 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HOWARD J RUBENSTEIN

NPI 1376598086 · CMS profile ID 244149

Allopathic & Osteopathic Physicians / Family Medicine

SARALAND, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 3; records 1–50 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1376598086?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HOWARD J RUBENSTEIN, NPI 1376598086, CMS profile ID 244149. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376598086?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). HOWARD J RUBENSTEIN, NPI 1376598086, CMS profile ID 244149. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376598086?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
HOWARD J RUBENSTEIN, NPI 1376598086, CMS profile ID 244149, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 3; records 1–50 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1376598086?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

108 matching records · $1,704.05 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 108 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 108.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $11.3612/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674675619 CMS
Novo Nordisk Inc $3.8812/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682574343 CMS
PFIZER INC. $14.0212/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673650593 CMS
Amarin Pharma Inc. $20.7812/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699276703 CMS
Novo Nordisk Inc $15.2911/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674675615 CMS
AstraZeneca Pharmaceuticals LP $10.8811/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685728115 CMS
Novo Nordisk Inc $4.0511/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682574339 CMS
Novo Nordisk Inc $2.4711/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682574347 CMS
PFIZER INC. $11.7211/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673653737 CMS
Amgen Inc. $12.3911/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662397749 CMS
Novo Nordisk Inc $5.4711/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682574335 CMS
Novo Nordisk Inc $1.2711/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682574351 CMS
Daiichi Sankyo Inc. $16.7810/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695393597 CMS
Lilly USA, LLC $18.7910/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657866223 CMS
Novo Nordisk Inc $5.5610/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682574312 CMS
PFIZER INC. $9.2610/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673170855 CMS
Novo Nordisk Inc $3.2610/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682574323 CMS
Novo Nordisk Inc $0.8210/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682574329 CMS
PFIZER INC. $13.3410/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673163575 CMS
Amarin Pharma Inc. $14.6710/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699227647 CMS
Novo Nordisk Inc $4.8310/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682574317 CMS
Novo Nordisk Inc $1.1010/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682574325 CMS
Amgen Inc. $13.2710/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662397745 CMS
Merck Sharp & Dohme Corporation $11.6810/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695818527 CMS
Novo Nordisk Inc $2.4409/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682574273 CMS
Novo Nordisk Inc $1.0309/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682574276 CMS
Merck Sharp & Dohme Corporation $9.7509/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695922135 CMS
Amgen Inc. $9.3309/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662397741 CMS
Novo Nordisk Inc $3.6709/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682574267 CMS
Novo Nordisk Inc $0.8709/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682574281 CMS
Amarin Pharma Inc. $18.2609/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699210503 CMS
Merck Sharp & Dohme Corporation $8.5609/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695753973 CMS
Novo Nordisk Inc $2.3708/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682574297 CMS
Novo Nordisk Inc $13.9408/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703500603 CMS
Amarin Pharma Inc. $14.7108/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699207171 CMS
Novo Nordisk Inc $4.7608/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682574287 CMS
Amgen Inc. $15.8708/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662397723 CMS
Novo Nordisk Inc $1.0108/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682574307 CMS
Shire North American Group Inc $12.3108/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637907673 CMS
Novo Nordisk Inc $4.5108/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682574293 CMS
Novo Nordisk Inc $1.9308/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682574303 CMS
Mylan Specialty L.P. $15.6608/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694793645 CMS
Merck Sharp & Dohme Corporation $16.1208/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695691231 CMS
GlaxoSmithKline, LLC. $16.9008/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670841965 CMS
Amgen Inc. $13.2408/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662397733 CMS
Novo Nordisk Inc $3.3607/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682574257 CMS
PFIZER INC. $12.2507/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672394239 CMS
Amgen Inc. $122.1107/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662397751 CMS
PFIZER INC. $13.1807/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672394243 CMS
Lilly USA, LLC $13.3207/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657852479 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,704.05 108
PY2020 $792.39 63
PY2021 $1,250.93 61
PY2022 $1,424.94 82
PY2023 $2,008.26 62
PY2025 $1,028.79 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $290,410.38 20
PY2024 Principal investigator $582,175.45 67
PY2023 Principal investigator $178,596.47 28
PY2022 Principal investigator $323,131.01 30
PY2021 Principal investigator $410,276.56 30
PY2020 Recipient $1,694.65 7
PY2020 Principal investigator $897,181.33 26
PY2019 Principal investigator $623,481.03 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,080.00 12/31/2023 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 998415645
Principal investigator 1 AstraZeneca Pharmaceuticals LP $29.63 12/31/2023 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 991127237
Principal investigator 1 AstraZeneca Pharmaceuticals LP $246.65 12/31/2023 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 991128631
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,450.00 12/20/2023 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension No dispute reported 06/30/2026 991141407
Principal investigator 1 ABBVIE INC. $5,588.39 12/07/2023 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 998411293
Principal investigator 1 ABBVIE INC. $5,882.50 12/04/2023 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 998410387
Principal investigator 1 ABBVIE INC. $2,404.55 11/09/2023 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 998407737
Principal investigator 1 ABBVIE INC. $3,705.02 11/09/2023 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 998407861
Principal investigator 1 ABBVIE INC. $2,531.10 11/07/2023 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 998406939
Principal investigator 1 ABBVIE INC. $3,900.00 11/07/2023 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 998406941
Principal investigator 1 ABBVIE INC. $2,840.00 10/26/2023 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 998405043
Principal investigator 1 ABBVIE INC. $1,500.00 10/19/2023 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 998404575
Principal investigator 1 ABBVIE INC. $13,029.58 10/19/2023 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 998404577
Principal investigator 1 ABBVIE INC. $1,500.00 10/19/2023 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 998404579
Principal investigator 1 Chiesi USA, Inc. $1,000.00 10/09/2023 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) No dispute reported 06/30/2026 1051611367
Principal investigator 1 ABBVIE INC. $2,404.55 09/14/2023 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 998399901
Principal investigator 1 ABBVIE INC. $17,351.81 08/24/2023 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 998396553
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,100.00 08/24/2023 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
An Open-label Extension Trial of the Phase III Lipid-lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given as Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C No dispute reported 06/30/2026 1017226357
Principal investigator 1 ABBVIE INC. $16,950.39 07/27/2023 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 998392583
Principal investigator 1 ABBVIE INC. $2,840.50 06/22/2023 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 998387867
Principal investigator 1 ABBVIE INC. $2,840.50 05/04/2023 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 998380615
Principal investigator 1 ABBVIE INC. $2,425.00 05/04/2023 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 998381179
Principal investigator 1 ABBVIE INC. $1,549.00 03/09/2023 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 998373261
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,000.00 03/08/2023 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 991133139
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,500.00 02/15/2023 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 991126393
Principal investigator 1 ABBVIE INC. $2,425.00 02/02/2023 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 998368101
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $62,097.30 01/18/2023 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF FIXED-DOSE BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN THE TREATMENT OF ADULTS WITH POST-TRAUMATIC STRESS DISORDER No dispute reported 06/30/2026 1014037997
Principal investigator 1 ABBVIE INC. $2,425.00 01/11/2023 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 998364779